Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

92%

12 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
7(53.8%)
Phase 4
5(38.5%)
Phase 2
1(7.7%)
13Total
Phase 3(7)
Phase 4(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT03222206Phase 4Completed

The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease

Role: collaborator

NCT03482180Phase 3Completed

Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

Role: lead

NCT01813253Phase 3Terminated

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Role: lead

NCT03258294Phase 4Unknown

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

Role: collaborator

NCT03026933Phase 3Completed

Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled

Role: lead

NCT02789592Phase 2Unknown

Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease

Role: collaborator

NCT02768077Phase 4Unknown

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

Role: lead

NCT02305355Phase 4Completed

Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia

Role: lead

NCT02035215Phase 3Unknown

Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia

Role: lead

NCT02087722Phase 3Completed

Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients

Role: lead

NCT00549692Phase 3Completed

Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy

Role: lead

NCT01450228Phase 3Completed

Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients

Role: lead

NCT00758927Phase 4Unknown

The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients

Role: collaborator

All 13 trials loaded